Jefferies Financial Group Boosts Celcuity (NASDAQ:CELC) Price Target to $134.00

Celcuity (NASDAQ:CELC) had its target price boosted by analysts at Jefferies Financial Group from $108.00 to $134.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Jefferies Financial Group’s price target would suggest a potential upside of 34.00% from the company’s previous close.

A number of other research analysts have also weighed in on CELC. Wolfe Research started coverage on Celcuity in a report on Tuesday, November 18th. They issued an “outperform” rating and a $110.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, October 8th. Craig Hallum lifted their price objective on shares of Celcuity from $96.00 to $108.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Stifel Nicolaus upped their price objective on shares of Celcuity from $68.00 to $115.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Finally, Guggenheim started coverage on shares of Celcuity in a report on Monday, September 22nd. They set a “buy” rating for the company. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $102.29.

Celcuity Trading Up 2.6%

Shares of Celcuity stock opened at $100.00 on Tuesday. The firm’s 50 day simple moving average is $72.56 and its two-hundred day simple moving average is $44.84. The firm has a market capitalization of $4.63 billion, a price-to-earnings ratio of -27.25 and a beta of 0.21. Celcuity has a 12-month low of $7.57 and a 12-month high of $103.06. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.13. Analysts predict that Celcuity will post -2.62 EPS for the current year.

Insider Activity at Celcuity

In other news, Director Richard E. Buller sold 3,900 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $96.73, for a total value of $377,247.00. Following the transaction, the director owned 7,260 shares in the company, valued at $702,259.80. This trade represents a 34.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 15.77% of the stock is owned by insiders.

Institutional Trading of Celcuity

Several large investors have recently made changes to their positions in CELC. Harvest Investment Services LLC purchased a new position in Celcuity in the 3rd quarter valued at $1,427,000. Voloridge Investment Management LLC purchased a new stake in shares of Celcuity during the third quarter worth $9,439,000. Verition Fund Management LLC acquired a new stake in shares of Celcuity in the third quarter valued at about $4,012,000. Scientech Research LLC purchased a new position in shares of Celcuity in the third quarter worth about $777,000. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Celcuity in the third quarter worth about $329,000. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.